Date: May 30, 2024

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov
Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On May 3, 2024, and pursuant to 18 V.S.A. § 4637(b), Day One Biopharmaceuticals, Inc. submitted a new drug introduction notice for the following (the "Product"):

NDC	Drug Description	WAC
82950-0001-16	ojemda (tovorafenib) 100mg Tablets, 16 Count	$ 33,916.00
82950-0001-20	ojemda (tovorafenib) 100mg Tablets, 20 Count	$ 33,916.00
82950-0001-24	ojemda (tovorafenib) 100mg Tablets, 24 Count	$ 33,916.00
82950-0012-01	ojemda (tovorafenib) (oral suspension) 300mg/12ml	$ 8,479.00

Day One Biopharmaceuticals, Inc. now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

1. **US and international marketing and pricing plans used at launch:** Day One Biopharmaceuticals, Inc declines to provide this information in accordance with 18 V.S.A. § 4637(d).

2. **Estimated volume of patients:** Additional information for estimated number of patients: The total addressable patient population of treatment-eligible, BRAF-altered relapse/refractory pediatric low grade glioma patients in US is approximately 2,000-3,000 annually

3. **Whether the FDA granted breakthrough therapy designation or priority review:** Yes granted breakthrough therapy and priority review

4. **Date and price of acquisition: N/A**

Thank you for your consideration.

Sincerely,

Marcus Farbstein, RPh

Director, Pricing & Contracting
Mobile: +1 703.662.1852
Marcus.Farbstein@DayOneBio.com
www.DayOneBio.com